JP2011522835A5 - - Google Patents

Download PDF

Info

Publication number
JP2011522835A5
JP2011522835A5 JP2011512705A JP2011512705A JP2011522835A5 JP 2011522835 A5 JP2011522835 A5 JP 2011522835A5 JP 2011512705 A JP2011512705 A JP 2011512705A JP 2011512705 A JP2011512705 A JP 2011512705A JP 2011522835 A5 JP2011522835 A5 JP 2011522835A5
Authority
JP
Japan
Prior art keywords
cells
suppressor
antibody
isolated
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011512705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011522835A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/046464 external-priority patent/WO2009149382A2/en
Publication of JP2011522835A publication Critical patent/JP2011522835A/ja
Publication of JP2011522835A5 publication Critical patent/JP2011522835A5/ja
Pending legal-status Critical Current

Links

JP2011512705A 2008-06-06 2009-06-05 抗ｃｄ８抗体は、細胞傷害性エフェクターのプライミングを遮断し、制御性ｃｄ８＋ｔ細胞の生成を導く Pending JP2011522835A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5964708P 2008-06-06 2008-06-06
US61/059,647 2008-06-06
PCT/US2009/046464 WO2009149382A2 (en) 2008-06-06 2009-06-05 Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells

Publications (2)

Publication Number Publication Date
JP2011522835A JP2011522835A (ja) 2011-08-04
JP2011522835A5 true JP2011522835A5 (https=) 2012-07-19

Family

ID=41398905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011512705A Pending JP2011522835A (ja) 2008-06-06 2009-06-05 抗ｃｄ８抗体は、細胞傷害性エフェクターのプライミングを遮断し、制御性ｃｄ８＋ｔ細胞の生成を導く

Country Status (14)

Country Link
US (1) US20090304659A1 (https=)
EP (1) EP2297204A4 (https=)
JP (1) JP2011522835A (https=)
KR (1) KR20110025812A (https=)
CN (1) CN102112491A (https=)
AU (1) AU2009255999A1 (https=)
BR (1) BRPI0915582A2 (https=)
CA (1) CA2728772A1 (https=)
IL (1) IL209798A0 (https=)
MX (1) MX2010013265A (https=)
NZ (1) NZ590197A (https=)
TW (1) TW201000130A (https=)
WO (1) WO2009149382A2 (https=)
ZA (1) ZA201100061B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5825966B2 (ja) * 2011-10-11 2015-12-02 株式会社日本バイオセラピー研究所 Ｃｄ５６陽性ｔ細胞増強方法
US10092597B2 (en) 2014-01-14 2018-10-09 The University Of Hong Kong Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice
WO2018085897A1 (en) * 2016-11-14 2018-05-17 Murdoch Childrens Research Institute Transplant rejection assay
KR102880156B1 (ko) * 2017-07-24 2025-11-05 리제너론 파마슈티칼스 인코포레이티드 항cd8 항체 및 이의 용도
EP3984554A4 (en) 2019-06-11 2023-11-08 ONO Pharmaceutical Co., Ltd. IMMUNOSUPPRESSANT
US20240209089A1 (en) * 2020-07-21 2024-06-27 Suzhou Smartnuclide Biopharmaceutical Co., Ltd. Cd8 binding polypeptide and use thereof
CN112156110B (zh) * 2020-09-15 2022-10-14 上海交通大学医学院 Cd8+抑制性t细胞在免疫调节中的应用及诱导方法
AU2022275666A1 (en) 2021-05-19 2023-12-07 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
CN120569191A (zh) 2022-11-23 2025-08-29 乔治亚大学研究基金公司 用于增加免疫应答的组合物及其使用方法
WO2024199407A1 (en) * 2023-03-31 2024-10-03 Qihan Hong Kong Limited Cancer immunotherapies using engineered cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178858A (en) * 1987-12-02 1993-01-12 Reichert Thomas A Method for prevention of graft versus host disease
CA1339840C (en) * 1988-12-16 1998-04-28 Kenneth Kortright Method and apparatus for screening cells or formed bodies with populations expressing selected characteristics
US5601828A (en) * 1989-03-15 1997-02-11 Tkb Associates Limited Partnership CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
CA2096530A1 (en) * 1990-11-23 1992-05-24 Thomas Russell Method and apparatus for screening microscopic cells utilizing light scatter techniques
US5876708A (en) * 1992-02-19 1999-03-02 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US6911220B1 (en) * 1992-02-19 2005-06-28 The General Hospital Corporation Allogeneic and xenogeneic transplantation
EP0939796B1 (en) * 1996-04-05 2009-05-27 South Alabama Medical Science Foundation Uses of oncofetal antigen specific cd4, cd8 cytotoxic and suppressor t cells and interleukin-10
JP2001511187A (ja) * 1997-02-28 2001-08-07 エンゾー セラピュウティクス， インコーポレイテッド 選択的免疫ダウンレギュレーション（ｓｉｄｒ）を行う新規プロセス
US6803036B1 (en) * 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
US20040022761A1 (en) * 2001-05-11 2004-02-05 Banchereau Jacques F Compositions and methods for producing antigen-presenting cells
ATE366801T1 (de) * 2002-09-27 2007-08-15 Bioe Inc Zusammensetzungen und verfahren zur trennung von zellen
WO2004083244A2 (en) * 2003-03-19 2004-09-30 Isogenis, Inc. Specific inhibition of allograft rejection
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
EP1674479A1 (en) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy
US20080031900A1 (en) * 2006-06-30 2008-02-07 Baylor Research Institute Dendritic Cells Generated Using GM-CSF and Interferon Alpha and Loaded with Heat-Treated and Killed Cancer Cells

Similar Documents

Publication Publication Date Title
JP2011522835A5 (https=)
JP7267976B2 (ja) 末梢免疫機能を調節するための方法及び組成物
EP3626817B1 (en) Methods of preparing anti-human papillomavirus antigen t cells
Van Driessche et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial
Zeng et al. Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance
AU2006249640B2 (en) Dendritic cell compositions and methods
TW200916581A (en) Paracrine signals from mesenchymal feeder cells and regulating expansion and differentiation of hepatic progenitors using same
Roberts et al. TNF blockade maintains an IL-10+ phenotype in human effector CD4+ and CD8+ T cells
de Haar et al. Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation
CN101514333B (zh) 一种免疫耐受型树突状细胞及其制备方法与专用培养基
EP2857498A1 (en) Composition for maturing dendritic cells, and method for preparing antigen-specific dendritic cells using same
LeÓn et al. Cytokine production by intestinal intraepithelial lymphocyte subsets in celiac disease
CN103589685B (zh) 一种dc细胞的快速制备方法
CN110607276A (zh) 高效扩增脐带血nk细胞的无血清培养方法
Gel’m et al. Functional activity of lymphocytes of healthy donors and cancer patients after culturing with IL-2 and IL-15
CN119286780B (zh) 一种t细胞的体外培养方法
CN108486055B (zh) 培养基及其在中央记忆型t淋巴细胞培养中的应用
Abediankenari et al. Comparison of several maturation inducing factors in dendritic cell differentiation
Li et al. The regulatory role of dendritic cells in the immune tolerance
CN113444688B (zh) 用于抗病毒抗肿瘤的人树突状细胞诱导方法及组合物
CN105219714A (zh) 一种用于激活肺癌特异性免疫反应的试剂盒
Naito et al. Mature dendritic cells generated from patient-derived peripheral blood monocytes in one-step culture using streptococcal preparation OK-432 exert an enhanced antigen-presenting capacity
CN102847145A (zh) 一种树突状细胞疫苗制备方法
Futalan et al. Effect of oxygen levels on the physiology of dendritic cells: implications for adoptive cell therapy
CN114350608B (zh) 一种诱导t细胞重编程为类nk细胞的组合物及其应用